These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26460271)

  • 1. Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
    Kim JB; Lee M; Park SY; Lee S; Kim HR; Lee HS; Yoon JH; Kim YJ
    Mol Med Rep; 2015 Dec; 12(6):8247-52. PubMed ID: 26460271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
    Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z
    Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT; Chao CC
    Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
    J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
    Lin S; Hoffmann K; Gao C; Petrulionis M; Herr I; Schemmer P
    J Pineal Res; 2017 Apr; 62(3):. PubMed ID: 28178378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
    Chen G; Nicula D; Renko K; Derwahl M
    Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
    Tao NN; Zhou HZ; Tang H; Cai XF; Zhang WL; Ren JH; Zhou L; Chen X; Chen K; Li WY; Liu B; Yang QX; Cheng ST; Huang LX; Huang AL; Chen J
    Oncotarget; 2016 Aug; 7(31):50117-50130. PubMed ID: 27367026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
    Luo L; Cai L; Luo L; Tang Z; Meng X
    Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
    Lu AQ; Lv B; Qiu F; Wang XY; Cao XH
    Oncol Rep; 2017 Apr; 37(4):2071-2078. PubMed ID: 28350139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.
    Kim JB; Park SY; Kim HR; Ahn YH; Jee HG; Lee JH; Yu SJ; Lee HS; Lee M; Yoon JH; Kim YJ
    Mol Med Rep; 2015 Jan; 11(1):263-8. PubMed ID: 25351906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
    Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW
    PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
    Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
    Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.